Swiss National Bank
GLUE icon

Swiss National Bank’s Monte Rosa Therapeutics GLUE Stock Holding History

Swiss National Bank’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33M Buy
96,300
+35,200
+58% +$665K ﹤0.01% 1869
2026
Q1 		$1.01M Buy
+61,100
New +$1.17M ﹤0.01% 2155
2023
Q4 		– Sell
-91,300
Closed -$437K – 2569
2023
Q3 		$437K Hold
91,300
– – ﹤0.01% 2534
2023
Q2 		$625K Buy
91,300
+49,500
+118% +$320K ﹤0.01% 2496
2023
Q1 		$326K Sell
41,800
-2,100
-5% -$14.6K ﹤0.01% 2597
2022
Q4 		$334K Hold
43,900
– – ﹤0.01% 2640
2022
Q3 		$359K Hold
43,900
– – ﹤0.01% 2646
2022
Q2 		$425K Buy
43,900
+16,400
+60% +$165K ﹤0.01% 2651
2022
Q1 		$386K Buy
27,500
+1,900
+7% +$26.4K ﹤0.01% 2633
2021
Q4 		$523K Buy
+25,600
New +$536K ﹤0.01% 2651

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Swiss National Bank's GLUE Position: Q2 2026 in Review

Swiss National Bank increased its Monte Rosa Therapeutics (GLUE) stake by 58% in Q2 2026, buying an estimated $665K and bringing the position to 96,300 shares worth $2.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1869.

Swiss National Bank first reported a position in GLUE in Q4 2021 and has held it in 10 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Swiss National Bank held 96,300 shares of Monte Rosa Therapeutics worth $2.33M as of Q2 2026.
  • Swiss National Bank bought 35,200 Monte Rosa Therapeutics shares in Q2 2026, an estimated $665K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1869 holding.
  • Swiss National Bank first reported a position in Monte Rosa Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.